Absolutely clueless is right. Invion has the rights to sell the inhaled version of nadolol and the rights to sell for nicotine dependance, where currently nadolol is not indicated. Someone using it for and marketing this for smoking cessation would be against the law.
Someone to partner and make the programs fully funded to completion will make some good money here imo.
Nadolol in smoking cessation - rival for champix BUT actually heals lungs as opposed to dealing with addiction (sales for champix 2008 $846M)
Inhaled nadolol - possible billion dollar sales based on stopping the beta arrestin pathway that causes excessive mucous and working locally in the lung (so limited adverse effects)
Inhaled zafirlukast - assuming the delivery device is effective - possible billion dollar market. Sales of singulair in 2011 were 3 billion odd.
Eagerly awaiting an announcement
IVX Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)